Knowledge Network Node
Chinese Archives of Traditional Chinese Medicine. 2018, (08) Core

Clinical Observation of Shenqi Fuzheng Injection Combined with Chemotherapy in Treatment of Non Small Cell Lung Cancer and The Regulation of Th17/Treg Cells in PatientsChinese Full Text

CHEN Rong;LI Miao;JI Baoyan;QI Shujun;Department of Oncology,Affiliated Hospital of Qinghai University;Oncology Department of Qinghai Cancer Hospital;Department of Oncology,Qinghai People’s Hospital;Department of Cancer and Radiotherapy,Affiliated Hospital of Qinghai University;

Abstract: Objective: To study the clinical effect of Shenqi Fuzheng Injection combined with chemotherapy in the treatment of non small cell carcinoma and the effect of Th17/Treg on peripheral blood. Methods: Seventy-nine patients with non small cell carcinoma treated in our hospital were randomly divided into the control group and the observation group. The patients in the control group were treated with TP regimen,and the observation group was treated with Shenqi Fuzheng Injection on the basis of the control group. The 2 groups were treated for 21 d as 1 chemotherapy cycle,and the2 periods was 1 course. We compared 2 groups’ peripheral blood Th17/Treg ratio,serum tumor markers（ CEA,CA125,CYFRA21-1 and NSE） levels. The survival curves were compared between the 2 groups. PFS and OS,clinical symptom score of 2 groups after treatment were evaluated. Results: In the treatment group after 1 and 2 cycles,CEA,CA125,CYFRA21-1 and NSE levels were significantly lower than those before treatment,and significantly lower than those of the control group（ P ＜ 0. 05）. The observation group’s Treg/Th17 was significantly higher than that before treatment（ P ＜0. 05）,while the control group’s was significantly lower than that before treatment（ P ＜ 0. 05）. After treatment,the observation group’s was significantly higher than the control group’s（ P ＜ 0. 05）. The observation group’s clinical symptom score after treatmentdecreased more significantlythan that of the control group（ P ＜ 0. 05）. The control group’s PFS was 13 months and median OS was 29 months. The observation group’s PFS was 19 months and median OS was 43 months. There was significant difference between 2 groups（ P ＜ 0. 05）. The ORR in the observation group was 73. 2%and DCR was 90. 2%. The ORR in the control group was 63. 2% and DCR was 76. 3%. The difference between the 2 groups was significant（ P ＜ 0. 05）. The total frequency of adverse reactions in the observation group was significantly less than that in the control group（ P ＜ 0. 05）. Conclusion: Shenqi Fuzheng Injection combined with chemotherapy can improve the clinical efficacy andthe immune function of patients with non-small cell carcinoma after operation,and the specific mechanism is related to the proportion of peripheral blood Th17/Treg.
Keywords：

Shenqi Fuzheng Injection; non small cell lung cancer; chemotherapy; Th17/Treg;

  • DOI：

    10.13193/j.issn.1673-7717.2018.08.054

  • Series：

  • Subject：

  • Classification Code：

    R734.2

Download the mobile appuse the app to scan this coderead the article.

Tips: Please download CAJViewer to view CAJ format full text.

Download: 351 Page: 1994-1997 Pagecount: 4 Size: 290K

Related Literature
  • Similar Article
  • Reader Recommendation
  • Associated Author